An Open-Label Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])
Avalyn Pharma Inc.
340 participants
Apr 17, 2025
Interventional
Conditions
Summary
The purpose of this protocol is to allow for subjects who have previously been enrolled in and completed an Avalyn Pharma Sponsored study of an inhaled antifibrotic, such as AP01, to continue therapy until drug approval, study termination, or withdrawal of the subject from the study.
Eligibility
Inclusion Criteria12
- Previously participated in an Avalyn-sponsored inhaled antifibrotic clinical
- study for subjects with either idiopathic pulmonary fibrosis (IPF) or
- progressive pulmonary fibrosis (PPF) and with the approval of the Study
- Physician. Previous participation is defined as: Having completed the final
- visit of the Treatment Period on the full dose of study drug (either active or
- placebo).
- Male subjects and female subjects of childbearing potential (FOCBP)
- agree to use highly effective contraception measures from the time of first
- dose of study drug (for the male subject) or the signing of the informed
- consent form (ICF) (for the female subject), during the study, and until 90
- days after the last dose of study drug. Subjects agree not to donate eggs
- or sperm during the same period.
Exclusion Criteria17
- Have not previously participated in an Avalyn-sponsored inhaled
- antifibrotic lead-in study or if the subject was permanently discontinued
- from the lead-in study for any reason. Subjects who discontinued study
- drug but continued to attend study visits are ineligible.
- Subjects who experienced an exacerbation of asthma or of chronic
- obstructive pulmonary disease (COPD) requiring oral or systemic
- corticosteroids within 3 months of Day 1 (Screening/Baseline Visit).
- Subjects who experienced an acute exacerbation of IPF or of PPF within 3
- months of Day 1 (Screening/Baseline Visit).
- Participation in a concurrent clinical study or in a clinical study in which
- any other investigational drug product aside from the Avalyn nebulized
- antifibrotic medication from their lead-in study was administered within
- the previous 30 days, or 5 half-lives of the previously administered
- investigational product, whichever is shorter. Subjects may be enrolled in
- registries.
- History of hypersensitivity and/or allergic reaction to pirfenidone or the
- excipients to be used in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day. All participants will receive 100 mg inhaled pirfenidone inhalation solution (AP01) taken twice daily using the eFlow Nebulizer System for until such a time that the drug is approved, the participant withdraws from the study, or the study is terminated. New patients will be trained to use the nebuliser at the first treatment visit. All patients will use the eFlow nebuliser to administer AP01. Hands on training for use and cleaning of the eFlow nebuliser will be performed by site personnel with patients using the study specific instructions for use and quick reference guide provided. The first treatment for new patients will be overseen by clinic personnel. A paper dosing diary will be used to monitor adherence along with returns of any unused investigational product.
Locations(26)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12625000246482